PRIORIX FDA approval expands supply of MMR vaccines
In a video for Contemporary Pediatrics®, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses an expansion of vaccine access likely to come with the FDA approval of the PRIORIX vaccine.
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief, Contemporary Pediatrics®; attending, division of infectious disease; medical director, international patient and destination services program at Ann & Robert H. Lurie Children’s Hospital of Chicago; and professor of pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, discussed the recent US Food and Drug Administration (FDA) approval of the PRIORIX (GSK plc) vaccine for measles, mumps, and rubella prevention. In a video, Tan highlighted the likely increase of vaccine availability due to the approval, which adds another manufacturer to the market and decreases the likelihood of shortages. Additionally, she noted that the PRIORIX vaccine can be used as a second dose to another, previously used MMR vaccine.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
